No, enoxaparin cannot replace rivaroxaban for long-term anticoagulation in rheumatic mitral stenosis with atrial fibrillation
For patients with rheumatic mitral stenosis and atrial fibrillation, vitamin K antagonists (warfarin) remain the standard of care—neither rivaroxaban nor enoxaparin are appropriate for long-term anticoagulation in this setting.
Why Rivaroxaban is Contraindicated
The most recent and authoritative guidelines explicitly exclude rivaroxaban and all DOACs in moderate-to-severe mitral stenosis:
- The 2024 ESC Guidelines state that DOACs (including rivaroxaban) are preferred over VKAs "except in patients with mechanical heart valves and mitral stenosis" 1
- The 2019 AHA/ACC/HRS Guidelines specify that "NOACs are recommended over warfarin in NOAC-eligible patients with AF (except with moderate-to-severe mitral stenosis or a mechanical heart valve)" 2
The landmark INVICTUS trial (2022-2024) definitively demonstrated that rivaroxaban was inferior to warfarin in patients with rheumatic mitral stenosis and AF, showing:
- Higher mortality rates in the rivaroxaban arm
- Higher drug discontinuation rates
- No reduction in bleeding compared to warfarin
- Failure to prove superiority for preventing stroke, systemic embolism, MI, and death 3, 4
Why Enoxaparin is Not Appropriate
Enoxaparin is a short-term anticoagulant, not designed for chronic stroke prevention in atrial fibrillation. Key limitations include:
- No evidence base: There are no studies evaluating enoxaparin for long-term stroke prevention in AF with mitral stenosis
- Practical barriers: Requires daily subcutaneous injections indefinitely, which is not feasible for chronic management
- Drug interaction data only: The FDA label notes that enoxaparin and rivaroxaban have additive anti-factor Xa effects when given together, but this describes acute co-administration, not chronic substitution 5
- Wrong indication: Enoxaparin is approved for VTE prophylaxis and treatment, not chronic AF stroke prevention
The Correct Answer: Warfarin
Warfarin (or another VKA) is the only evidence-based anticoagulant for patients with rheumatic mitral stenosis and atrial fibrillation. Management should include:
- Target INR 2.0-3.0, maintained >70% of the time 1
- Weekly INR monitoring during initiation, then at least monthly when stable 2
- Reassessment of stroke and bleeding risks at periodic intervals 2
Critical Pitfalls to Avoid
- Do not use rivaroxaban in moderate-to-severe mitral stenosis—this is explicitly contraindicated by all major guidelines and proven inferior by INVICTUS
- Do not substitute enoxaparin for chronic anticoagulation—it lacks efficacy data, requires injections, and is impractical long-term
- Do not assume DOAC data from nonvalvular AF applies to rheumatic mitral stenosis—the pathophysiology and thrombotic risk are fundamentally different
The small pilot study (RISE MS) showing potential promise for rivaroxaban 6 and observational data 7 are insufficient to override guideline recommendations and the definitive negative results from INVICTUS.